Kaempferol: A Potential Treatment for Emotional Stress-Aggravated Prostate Cancer Metastasis
/0 Comments/in Preclinical Research/by MaxProtac NP18: A New Hope for Prostate Cancer Treatment
/0 Comments/in Preclinical Research, PROTACs/by MaxThe Future of Cancer Treatment (pan-cancer): A 3-in-1 Antibody Design
/0 Comments/in Immunotherapy, Not PCa related, Preclinical Research/by MaxNodularin-R Enhances Abiraterone’s Effectiveness Against Castration-Resistant Prostate Cancer In Vivo
/0 Comments/in Preclinical Research/by MaxNew Hope for Castration-Resistant Prostate Cancer: Targeting EZH2
/0 Comments/in Preclinical Research/by MaxPersonalized Treatment for Advanced Prostate Cancer: The Power of Multi-Tracer PET Imaging
/0 Comments/in Preclinical Research/by MaxCTT2274: A Potential Game-Changer for Metastatic Prostate Cancer Treatment…start hating the word “potential”
/0 Comments/in Preclinical Research/by MaxImmunotherapy (potential) Breakthrough: Turning Cold Tumors Hot, Prostate Cancer is the Perfect Candidate
/0 Comments/in Immunotherapy, Preclinical Research/by MaxAnother Potential Breakthrough: 3-in-1 Antibody Shows Promise
/0 Comments/in Immunotherapy, Not PCa related, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Phase 1: SYN608 Targets DNA Repair in HRR-Deficient Prostate and Other Solid Tumors July 30, 2025
- Phase 1 Trial of a Triple Combination: 177Lu-PSMA-I&T, Olaparib, and Pembrolizumab July 30, 2025
- LYA914: A Novel Oral PROTAC Targeting Androgen Receptor Variants in Prostate Cancer July 30, 2025
- Phase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond July 29, 2025